Research
Hormonal
Supplemental intakes of EPA and DHA combined up to 5 g/day do not significantly affect glucose homeostasis in healthy or diabetic subjects.
If you have diabetes or are healthy, taking up to 5g/day of combined EPA/DHA will not negatively affect your blood sugar control. You can take this dose without worrying about glucose homeostasis.
GoodRefutesHIGH confidence
Supplemental intakes of EPA and DHA combined at doses up to 5 g/day consumed for up to 12 weeks do not significantly affect glucose homeostasis in healthy or diabetic subjects, nor do they induce changes in immune functions which might raise concern in relation to the risk of infections or inappropriate activation of inflammatory responses.
Why this rating
Based on human intervention studies reviewed by EFSA.
Source
Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)
EFSA Panel on Dietetic Products et al. · EFSA Journal · 2012
DOI 10.2903/j.efsa.2012.2815
Meta-analysisCited 358×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Supplemental intakes of EPA and DHA combined up to 5 g/day, and EPA alone up to 1.8 g/day, do not raise safety concerns for adults.Strong
- Long-term supplemental intakes of combined EPA and DHA up to 5 g/day do not increase the risk of spontaneous bleeding episodes or bleeding complications, even in subjects at high risk of bleeding.Good
- Supplemental intakes of EPA and DHA combined at doses of 2-6 g/day, and DHA at 2-4 g/day, increase LDL-cholesterol by about 3%, but this increase is accompanied by a decrease in triglycerides and does not adversely affect cardiovascular disease risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →